Clinical Trial

Irrisept Solution for Instrumented Spine Surgery

Recruiting
View on ClinicalTrials.gov →
Summary
Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacteriocidal properties to eliminate hardware inoculation, thereby minimizing the risk of deep space infection, while obviating the risk of seroma development.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2028-04 2026-08-15
minor Completion pushed: 2026-09-30 -> 2028-04 2026-08-15
Trial Details
NCT Number NCT06439953
Lead Sponsor Rhode Island Hospital
Conditions Post-Op Complication, Spine Surgery, Site Infection, Surgical Site Infection, Spinal Instrumentation, Index Spinal Instrumentation, Layer-by-Layer Closure, Locoregional Flap-Based Closure
Enrollment 200 participants
Start Date 2024-10-01
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-14